keyword
https://read.qxmd.com/read/38581481/genomic-ancestry-and-cancer-among-latin-americans
#21
JOURNAL ARTICLE
Alejandro Ruíz-Patiño, Leonardo Rojas, Jairo Zuluaga, Oscar Arrieta, Luis Corrales, Claudio Martín, Sandra Franco, Luis Raez, Christian Rolfo, Natalia Sánchez, Andrés Felipe Cardona
Latin American populations, characterized by intricate admixture patterns resulting from the intermingling of ancestries from European, Native American (NA) Asian, and African ancestries which result in a vast and complex genetic landscape, harboring unique combinations of novel variants. This genetic diversity not only poses challenges in traditional population genetics methods but also opens avenues for a deeper understanding of its implications in health. In cancer, the interplay between genetic ancestry, lifestyle factors, and healthcare disparities adds a layer of complexity to the varying incidence and mortality rates observed across different Latin American subpopulations...
April 6, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38581448/integration-of-pan-cancer-cell-line-and-single-cell-transcriptomic-profiles-enables-inference-of-therapeutic-vulnerabilities-in-heterogeneous-tumors
#22
JOURNAL ARTICLE
Weijie Zhang, Danielle Maeser, Adam Lee, Yingbo Huang, Robert F Gruener, Israa G Abdelbar, Sampreeti Jena, Anand G Patel, R Stephanie Huang
Single-cell RNA-sequencing (scRNA-seq) greatly advanced the understanding of intratumoral heterogeneity by identifying distinct cancer cell subpopulations. However, translating biological differences into treatment strategies is challenging due to a lack of tools to facilitate efficient drug discovery that tackles heterogeneous tumors. Developing such approaches requires accurate prediction of drug response at the single-cell level to offer therapeutic options to specific cell subpopulations. Here, we developed a transparent computational framework (nicknamed scIDUC) to predict therapeutic efficacies on an individual-cell basis by integrating single-cell transcriptomic profiles with large, data-rich pan-cancer cell line screening datasets...
April 6, 2024: Cancer Research
https://read.qxmd.com/read/38577694/post-therapeutic-squamous-cell-transformation-of-a-metastatic-prostate-adenocarcinoma-with-comparison-of-molecular-profiles-a-case-report-and-review-of-the-literature
#23
Peizi Li, George K Haines, Qiusheng Si, Brett Baskovich
Transformation of primary prostate adenocarcinoma to squamous cell carcinoma after initial treatment with chemotherapy and hormonal therapy is extremely rare and typically results in rapid treatment-refractory disease progression and death. Here, we present a case of a 64-year-old man who was initially diagnosed with metastatic prostate adenocarcinoma (positive PSA and NKX3.1 stains, total PSA 747.2 ng/ml) to the thoracic spine (T8) in 2019. The patient received androgen deprivation therapy and chemotherapy with good response (PSA 2...
2024: International Journal of Clinical and Experimental Pathology
https://read.qxmd.com/read/38577608/identification-of-molecular-subtype-and-prognostic-signature-for-prostate-adenocarcinoma-based-on-neutrophil-extracellular-traps
#24
JOURNAL ARTICLE
Yanfen Zheng, Hui Sun, Shanshan Yang, Wei Liu, Guanmin Jiang
Background : Prostate adenocarcinoma (PRAD) is one of the most common cancers in male. Increasing evidences pointed out that Neutrophil Extracellular Traps (NETs) play an important role in tumor angiogenesis, tumor metastasis and drug resistance. However, limited systematic studies regarding the role of NETs in PRAD have been performed. Identification of biomarkers based on NETs might facilitate risk stratification which help optimizing the clinical strategies. Methods : NETs-related genes with differential expressions were identified between PRAD and adjacent normal tissues in TCGA-PRAD dataset...
2024: Journal of Cancer
https://read.qxmd.com/read/38576998/predicting-prostate-cancer-progression-with-a-multi-lncrna-expression-based-risk-score-and-nomogram-integrating-isup-grading
#25
JOURNAL ARTICLE
Sabrina Ledesma-Bazan, Florencia Cascardo, Juan Bizzotto, Santiago Olszevicki, Elba Vazquez, Geraldine Gueron, Javier Cotignola
Prostate cancer is a highly heterogeneous disease; therefore, estimating patient prognosis accurately is challenging due to the lack of biomarkers with sufficient specificity and sensitivity. One of the current challenges lies in integrating genomic and transcriptomic data with clinico-pathological features and in incorporating their application in everyday clinical practice. Therefore, we aimed to model a risk score and nomogram containing long non-coding RNA (lncRNA) expression and clinico-pathological data to better predict the probability of prostate cancer progression...
June 2024: Non-Coding RNA Research
https://read.qxmd.com/read/38576208/is-fragmentation-of-prostate-core-biopsies-inevitable-a-quality-improvement-initiative
#26
JOURNAL ARTICLE
Krithika Shenoy, Richard J Cote, Gayathri Kini, Mary Anthes-Bartlow, Vijayalakshmi Padmanabhan
CONTEXT.—: Core biopsies are standard of care for diagnosis and surveillance of prostate cancer. Fragmentation makes numeric assessment of cancer challenging and increases risk of inaccurate staging with direct implications on management. OBJECTIVE.—: To determine factors responsible for fragmentation at our institution. DESIGN.—: Prostate core biopsies performed at 2 hospital sites during 1 week were prospectively identified...
April 5, 2024: Archives of Pathology & Laboratory Medicine
https://read.qxmd.com/read/38571290/development-of-a-multigenomic-liquid-biopsy-prostest-for-prostate-cancer-in-whole-blood
#27
JOURNAL ARTICLE
Irvin M Modlin, Mark Kidd, Ignat A Drozdov, Martin Boegemann, Lisa Bodei, Jolanta Kunikowska, Anna Malczewska, Christof Bernemann, Srinivas V Koduru, Kambiz Rahbar
INTRODUCTION: We describe the development of a molecular assay from publicly available tumor tissue mRNA databases using machine learning and present preliminary evidence of functionality as a diagnostic and monitoring tool for prostate cancer (PCa) in whole blood. MATERIALS AND METHODS: We assessed 1055 PCas (public microarray data sets) to identify putative mRNA biomarkers. Specificity was confirmed against 32 different solid and hematological cancers from The Cancer Genome Atlas (n = 10,990)...
April 3, 2024: Prostate
https://read.qxmd.com/read/38568057/development-synthesis-and-validation-of-improved-c-myc-max-inhibitors
#28
JOURNAL ARTICLE
Sümbül Yıldırım, Fatih Kocabaş, Arif Mermer
The pathophysiological foundations of various diseases are often subject to alteration through the utilization of small compounds, rendering them invaluable tools for the exploration and advancement of novel therapeutic strategies. Within the scope of this study, we meticulously curated a diverse library of novel small compounds meticulously designed to specifically target the c-Myc/Max complex. We conducted in vitro examinations of novel c-Myc inhibitors across a spectrum of cancer cell lines, including PANC1 (pancreatic adenocarcinoma), MCF7 (breast carcinoma), DU-145 (prostate carcinoma), and A549 (lung cancer)...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38567582/evaluation-of-the-effect-of-prostate-diameters-on-erectile-dysfunction-in-patients-who-underwent-low-anterior-resection
#29
JOURNAL ARTICLE
A Senturk, F Mutlu
OBJECTIVE: Male erectile dysfunction is an important complication of rectal surgery. In this research, the effect of prostate dimensions on the development of postoperative erectile dysfunction in patients diagnosed with mid-rectum adenocarcinoma who underwent low anterior resection (LAR) is examined. PATIENTS AND METHODS: Thirty-one male patients diagnosed as mid-rectal adenocancer were included. The International Index of Erectile Function (IIEF) questionnaire was used to determine the patients' pre and postoperative erectile dysfunction levels, and the level of relationship between the change in these IIEF scores and prostate measurements determined by computed tomography were evaluated...
March 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38567167/synchronous-papillary-thyroid-cancer-and-colorectal-cancer-in-a-young-patient-with-a-chek2-mutation
#30
Sydney Brooke Hoskins, Leslie Torgerson
INTRODUCTION: Mutations of CHEK2 are usually inherited and have been implicated in breast cancers, colorectal cancers, thyroid cancers, kidney cancers, and prostate cancers. The CHEK2 gene codes for checkpoint kinase 2 protein which is an effector in the ATM-CHEK2-p53 pathway and responds to DNA double-strand breaks. CASE PRESENTATION: We describe a unique case of a 29-year-old Canadian female who presented with synchronous papillary thyroid carcinoma and rectal adenocarcinoma who was subsequently found to have a sporadic CHEK2 (checkpoint kinase 2) mutation...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38565023/primary-mucinous-adenocarcinoma-of-the-urethra-a-contemporary-clinicopathologic-analysis-of-17-patients
#31
JOURNAL ARTICLE
Alaaeddin Alrohaibani, Adeboye O Osunkoya
Mucinous adenocarcinoma of the urethra is rare. Here we performed a contemporary clinicopathologic analysis of this entity in both male and female patients. All cases with secondary tumors involving the urethra were excluded. Clinicopathologic parameters and follow up was obtained. Seventeen patients were included in the study, 9/17 (53 %) male and 8/17 (47 %) female. The mean patient age was 68 years (range: 53-88 years). The majority (11/17, 65 %) of patients were African American, with an even greater incidence (7/8, 87 %) in female patients...
March 28, 2024: Pathology, Research and Practice
https://read.qxmd.com/read/38563224/stem-cell-dynamics-and-cellular-heterogeneity-across-lineage-subtypes-of-castrate-resistant-prostate-cancer
#32
JOURNAL ARTICLE
Michael L Beshiri, Brian J Capaldo, Ross Lake, Anson T Ku, Danielle Burner, Caitlin M Tice, Crystal Tran, Julianna Kostas, Aian Neil Alilin, Juan Juan Yin, Supreet Agarwal, Samantha A Morris, Fatima H Karzai, Tamara L Lotan, William L Dahut, Adam G Sowalsky, Kathleen Kelly
To resist lineage-dependent therapies such as androgen receptor inhibition, prostate luminal epithelial adenocarcinoma cells often adopt a stem-like state resulting in lineage-plasticity and phenotypic heterogeneity. Castrate resistant prostate adenocarcinoma can transition to neuroendocrine and occasionally to amphicrine, co-expressed luminal and neuroendocrine, phenotypes. We developed CRPC patient-derived organoid models that preserve heterogeneity of the originating tumor, including an amphicrine model displaying a range of luminal and neuroendocrine phenotypes...
April 2, 2024: Stem Cells
https://read.qxmd.com/read/38562999/an-androgen-receptor-based-signature-to-predict-prognosis-and-identification-of-orc1-as-a-therapeutical-target-for-prostate-adenocarcinoma
#33
JOURNAL ARTICLE
Linjin Li, Dake Chen, Xiang Chen, Jianlong Zhu, Wenshuo Bao, Chengpeng Li, Feilong Miao, Rui Feng
BACKGROUND: Aberrant activation of androgen receptor (AR) signaling plays a crucial role in the progression of prostate adenocarcinoma (PRAD) and contributes significantly to the development of enzalutamide resistance. In this study, we aimed to identify a novel AR-driven signature that can predict prognosis and endows potentially reveal novel therapeutic targets for PRAD. METHODS: The Seurat package was used to preprocess the single-cell RNA sequencing (scRNA-seq)...
2024: PeerJ
https://read.qxmd.com/read/38562398/gamut-of-urological-diseases-in-a-tertiary-hospital-in-north-central-nigeria
#34
JOURNAL ARTICLE
Ugbede Emmanuel Oyibo, John C Onwukwe
CONTEXT: Worldwide, urological disorders vary from one topography to another. An in-depth understanding of their distribution in each region could serve as a basis for the distribution of manpower, equipment's alongside determine policy formulation and training. AIMS: This study enumerates the annual frequency and distribution of urological disorders at the Federal Medical Centre, Keffi. SETTINGS AND DESIGN: A cross-sectional retrospective study from November 2021 to November 2022 of all new patients who attended the urology outpatient clinic, emergency department as well as those who had surgical interventions at the Federal Medical Centre, Keffi, Nasarawa State...
2024: Journal of the West African College of Surgeons
https://read.qxmd.com/read/38562314/a-case-of-budd-chiari-syndrome-secondary-to-tumor-thrombosis
#35
Nirmay Sonar, Zaynah Sadiq, Gurvinder Kaur, Shohan Pervaze, Nicholas Cook
Budd-Chiari syndrome (BCS) is a rare constellation of conditions due to obstruction of venous flow from anatomical levels ranging from the hepatic veins to the confluence of the inferior vena cava (IVC) and right atrium. The resulting retrograde flow of blood leads to hepatomegaly, ascites, and liver failure among other features. Our case highlights the clinical features, diagnostic challenges, and management of a patient with a tumor thrombus from a metastatic prostate adenocarcinoma in a 67-year-old male leading to BCS...
March 2024: Curēus
https://read.qxmd.com/read/38562047/gata3-expression-in-prostatic-adenosquamous-carcinoma-a-potential-diagnostic-pitfall
#36
JOURNAL ARTICLE
Susan K Potterveld, Sean R Williamson, Khaleel I Al-Obaidy, Mahmut Akgul, Emily Chan, Giovanna A Giannico, Ankur R Sangoi
Urothelial carcinoma and prostatic adenocarcinoma can have overlapping histologic features and in some instances pose challenges to pathologists. GATA binding protein 3 (GATA3) immunohistochemistry (IHC) is a well-established tool to aid in this specific diagnostic dilemma as it has been shown to be a sensitive marker for urothelial carcinoma and a putatively specific marker in excluding prostatic adenocarcinoma. However, in encountering an index tumor of prostatic adenosquamous carcinoma positive for GATA3, herein we sought to investigate this potential diagnostic pitfall in a larger series of tumors...
April 1, 2024: International Journal of Surgical Pathology
https://read.qxmd.com/read/38557789/protein-kinase-d2-aurora-kinase-a-erk1-2-signalling-axis-drives-neuroendocrine-differentiation-of-epithelial-ovarian-cancer
#37
JOURNAL ARTICLE
Abha Sachdeva, Adhiraj Roy, Supratim Mandal
Epithelial ovarian cancer (EOC) is deadliest gynecological malignancy with poor prognosis and patient survival. Despite development of several therapeutic interventions such as poly-ADP ribose polymerase (PARP) inhibitors, EOC remains unmanageable and discovery of novel early detection biomarkers and treatment targets are highly warranted. Although neuroendocrine differentiation (NED) is implicated in different human cancers including prostate adenocarcinoma and lung cancer, mechanistic studies concerning NED of epithelial ovarian cancer are lacking...
April 1, 2024: Molecular and Cellular Biochemistry
https://read.qxmd.com/read/38555410/the-association-of-patient-and-disease-characteristics-with-the-overtreatment-of-low-risk-prostate-cancer-from-2010-to-2016
#38
JOURNAL ARTICLE
Cooper Desmond, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Peter Chang, Andrew Wagner, Simon P Kim, Nima Aghdam, Aria F Olumi, Boris Gershman
BACKGROUND: Although active surveillance is the preferred management for low-risk prostate cancer (PCa), some men remain at risk of overtreatment with definitive local therapy. We hypothesized that baseline characteristics may be associated with overtreatment and represent a potential source of health disparities. We therefore examined the associations of patient and disease characteristics with the surgical overtreatment of low-risk PCa. METHODS: We identified men aged 45-75 years with cT1 cN0 cM0 prostate adenocarcinoma with biopsy Gleason score 6 and PSA < 10 ng/ml from 2010-2016 in the National Cancer Database (NCDB) and who underwent radical prostatectomy (RP)...
March 30, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38554337/prognostic-micrornas-as-biomarkers-for-prostate-cancer
#39
JOURNAL ARTICLE
Hema Palanisamy, Jeevitha Priya Manoharan, Subramanian Vidyalakshmi
OBJECTIVE: Prostate cancer is the second largest cancer, most commonly diagnosed in men. Several studies reveal that miRNAs (microRNAs) are involved in various stages of prostate cancer. miRNAs are a family of small non-coding RNA species that have been implicated in the post-transcriptional regulation of gene expression. The present in silico study aims at identifying miRNA biomarkers that are significantly associated with the regulation of genes involved in prostate cancer. METHODS: Dataset of miRNA and mRNA of prostate adenocarcinoma patients and controls was downloaded from The Cancer Genome Atlas (TCGA), and differential gene expression analysis was carried out...
January 1, 2024: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38551737/differential-tempol-effects-in-prostatic-cancer-angiogenesis-and-short-and-long-term-treatments
#40
JOURNAL ARTICLE
Felipe Rabelo Santos, Isabela Maria Urra Rossetto, Fabio Montico, Celina de Almeida Lamas, Valéria Helena Alves Cagnon
Prostate cancer (PCa) is the second cause of cancer death among men worldwide. Several processes are involved in the development and progression of PCa such as angiogenesis, inflammation and oxidative stress. The present study investigated the effect of short- or long-term Tempol treatment at different stages of prostate adenocarcinoma progression, focusing on angiogenic, proliferative, and stromal remodeling processes in TRAMP mice. The dorsolateral lobe of the prostate of TRAMP mice were evaluated at two different stages of PCa progression; early and late stages...
March 29, 2024: Journal of Molecular Histology
keyword
keyword
68531
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.